Nonalcoholic Steatohepatitis (NASH) (now known as Metabolic Dysfunction-Associated Steatohepatitis or MASH) represents a significant and growing challenge in clinical practice, with its progression to cirrhosis and hepatocellular carcinoma posing serious risks for patients. The exciting new conditional commercial launch of …